Bogdanos Dimitrios P, Daniil Zoi, Zakynthinos Epaminondas, Gourgoulianis Konstantinos, Sakkas Lazaros I
Department of Rheumatology and Clinical Immunology.
Department of Respiratory Medicine, and.
Mediterr J Rheumatol. 2020 Mar 31;31(1):94-97. doi: 10.31138/mjr.31.1.94. eCollection 2020 Mar.
The current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. We wish to enter the ongoing debate as to whether this well-known drug must be given to Greek COVID-19-infected patients, especially those with pneumonia. Our arguments are based on the existing data and the capacity of the Greek health system to afford potent anti-viral treatments, which are under immense investigation. We propose several suggestions related to treatment of COVID-19 pneumonia with chloroquine/hydroxychloroquine that we think must be taken into consideration to fit the evolving situation of the pandemic in Greece.
目前用于治疗自身免疫性风湿疾病的氯喹和/或羟氯喹，在治疗由冠状病毒2（SARS-CoV-2）引起的严重急性呼吸综合征或感染新冠肺炎且患有肺炎的患者方面，正受到激烈讨论。我们希望参与到这场正在进行的辩论中，即这种知名药物是否必须用于希腊感染新冠肺炎的患者，尤其是那些患有肺炎的患者。我们的观点基于现有数据以及希腊医疗系统提供强效抗病毒治疗的能力，而这些治疗正在深入研究中。我们针对使用氯喹/羟氯喹治疗新冠肺炎肺炎提出了若干建议，我们认为必须考虑这些建议以适应希腊疫情的不断变化的形势。
